Online citations, reference lists, and bibliographies.

Brain Metastases In Patients With Neuroendocrine Neoplasms: Risk Factors And Outcome

Sebastian Krug, Freya Teupe, Patrick Michl, Thomas M. Gress, Anja Rinke
Published 2019 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
BackgroundBrain metastases (BM) are rarely reported in patients with neuroendocrine carcinoma (NEC) of non-lung origin and neuroendocrine tumors (NET) of the gastroenteropancreatic (GEP) or bronchopulmonary system. However, symptomatic brain metastases are associated with dismal prognosis, so early detection and treatment could be advisable.MethodsWe retrospectively analyzed 51 patients with GEP-NEN and bronchopulmonary NEN excluding small cell lung cancer. All patients were treated at the University Hospital Marburg and Halle (Saale) between 2000 and 2017. The median overall survival (mOS) and mOS after diagnosis of brain metastases (BM) were calculated using Kaplan-Meier analysis. Risk factors for poor prognosis were evaluated using univariate and multivariate Cox regression method.ResultsOverall, 51 patients with a median age of 58 years presented BM. Lung (n = 23, 45.1%) was the most frequent primary localization. Most patients had NEC (n = 31, 60.8%), including 26 carcinomas (51%) with Ki-67 indices > 55%. Singular BM were present in 16 patients (31.4%), but 21 patients (41.2%) had multiple lesions. Overall, the median period from first diagnosis of the tumor disease up to diagnosis of brain metastasis was 5.0 months. Palliative radiation was the most common therapy (n = 31, 60.8%). Median OS after initial diagnosis and diagnosis of BM was 23.0 and 11.0 months, respectively. Univariate and multivariate analysis for prognostic indicators depicted differentiation (NEC HR 4.2, 95% CI 1.1–16.1) and age (≥60 HR 3.0, 95% CI 1.2–7.5) as markers for poor outcome.ConclusionsOverall, the risk for symptomatic brain metastases is low in GEP-NEN and bronchopulmonary NEN patients. Age above 60 and poor tumor differentiation may deteriorate the overall survival. Therefore, screening for brain metastases could be advisable in NEC patients.
This paper references
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.
Halfdan Sørbye (2013)
ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site
Marianne E. Pavel (2016)
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.
M. Caplin (2015)
Carcinoid metastasis to the brain. Cancer
R Hlatky (2004)
Gamma Knife radiosurgery for brain metastases from pulmonary large cell neuroendocrine carcinoma: a Japanese multi-institutional cooperative study (JLGK1401).
T. Kawabe (2016)
Neurologic complications of carcinoid. Neurology
RA Patchell (1986)
Neurologic complications of carcinoid
Roy A. Patchell (1986)
Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO)
R. Soffietti (2017)
Single Brain Metastases of Carcinoid Tumors
F. Maiuri (2004)
Clinicopathological analysis in patients with neuroendocrine tumors that metastasized to the brain
J. Akimoto (2015)
Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival.
Babak Givi (2006)
Identifying Prognostic Factors for Well-Differentiated Metastatic Pancreatic Neuroendocrine Tumours: A Retrospective International Multicentre Cohort Study
P. Jimenez-Fonseca (2018)
TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system
G. Rindi (2006)
Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome.
Henning Jann (2011)
Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.
J. Naidoo (2016)
ENETS Consensus Guidelines for the Management of Brain, Cardiac and Ovarian Metastases from Neuroendocrine Tumors
M. Pavel (2010)
[Neuroendocrine tumours of the GI tract--data from the German NET Registry].
Naseema Begum (2014)
Carcinoid metastasis to the brain.
R. Hlatký (2004)
TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system
Guido Rindi (2007)
Neurologic disorders in 432 consecutive patients with small cell lung carcinoma.
T. Seute (2004)
The role of radiation therapy in the treatment of locally unresectable or metastatic carcinoid tumors.
Karen D. Schupak (1991)
Bone Metastases in Patients with Neuroendocrine Neoplasm: Frequency and Clinical, Therapeutic, and Prognostic Relevance
Michael W. Scharf (2017)
Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.
H. Aoyama (2006)
Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
Staffan Welin (2011)
Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).
Rocio Garcia-Carbonero (2010)
Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group.
A. Aupérin (1999)
Recent trends in epidemiology of brain metastases: an overview.
Emeline Tabouret (2012)
Brain carcinoid metastases: outcomes and prognostic factors.
Grant W. Mallory (2013)
TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study.
G. Rindi (2012)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar